Pharmacokinetics and Safety of 'CG-745 IV' and 'CG-750' in Healthy Male Adults

• Status: Completed
• Trial end date: 2021-05-19
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, placebo-controlled, dose-escalation, crossover study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: CrystalGenomics, Inc.

Criteria

Key Inclusion Criteria:

• Subject who signed voluntarily the written agreement after understanding the purpose, contents, the properties and expected adverse effects of investigational product

• Subject who is considered to be appropriate for the study according to the judgment of investigator based on physical examination, clinical laboratory test, electrocardiogram, vital sign and questionnaire

Key Exclusion Criteria:

• Subject with clinically meaningful and relevant disease in liver, kidney, nervous system, respiratory system, endocrine system, blood and tumor, cardiovascular system, urinary system and mental system

• Subject with sensitive reaction in HDAC inhibitor or another drug

• Subject who participated in another clinical trial or bioequivalent study with past 6 weeks

• Subject who is not considered to be appropriate for the study according to the judgment of investigator